Post Graduate Institute Of Medical Education And Research, Chandigarh
Clinical trials sponsored by Post Graduate Institute Of Medical Education And Research, Chandigarh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy aims to slow lung scarring in hypersensitivity pneumonitis Results expected Sep 2026 (estimated)
- New sedative may make lung exams safer and smoother Results expected Oct 2026 (estimated)
- Which feeding method works best after pancreatic necrosis drainage? Results expected Dec 2026 (estimated)
- Tiny plastics, big trouble? new study probes microplastic impact on liver disease Results expected Jan 2027 (estimated)
- Steroid combo may improve tough lung fungus treatment Results expected Jan 2027 (estimated)
-
Can a diabetes drug shrink fatty liver in thyroid patients?
Disease control OngoingThis trial tests whether dapagliflozin, a drug used for diabetes, can reduce liver fat in people with underactive thyroid (hypothyroidism) who also have non-alcoholic fatty liver disease (NAFLD). Half of the 50 participants will take dapagliflozin daily, and the other half will t…
Early phase 1 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy aims to slow lung scarring in hypersensitivity pneumonitis
Disease control OngoingThis phase 4 trial tests whether adding mycophenolate mofetil (MMF) to standard prednisolone treatment works better than prednisolone alone for fibrotic hypersensitivity pneumonitis, a lung condition where scarring makes breathing hard. About 144 adults with at least 40% predicte…
Phase 4 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC